Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	44D0864535	05/09/2018
Name of Provider or Supplier	**Street Address, City, State**	
Tennessee Oncology Pllc	2004 Hayes Street, Suite 350, Nashville, TN	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: ALWAYS REFER TO STANDARD TAG IN APPROPRIATE LAB SPECIALTY. Hematology: The laboratory failed to maintain satisfactory participation in two out of three events for the Cell I.D. or automated white blood cell (WBC) differential, resulting in the first unsuccessful proficiency testing (PT) occurrence for the Cell I.D. or automated WBC differential analyte. (Refer to D2130)
D2130	HEMATOLOGY CFR(s): 493.851(f)

	Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: The findings include: 1) Review of the Casper 155 report revealed the Cell ID 2017 event one score is 40%, event two score is 60%. 2) Review of the laboratory's 2017 Medical Laboratory Evaluation (MLE)-M1 PT records event one cell BC-1, BC-2, BC-5 had unacceptable grades, resulting in a score of 40%, event two 2017 MLE-M2 cell BC-9, BC-10 had unacceptable grades, resulting in a score of 60%,